|
1
|
Jonasch E, Gao J and Rathmell WK: Renal
cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miyazaki K, Kawamoto T, Tanimoto K,
Nishiyama M, Honda H and Kato Y: Identificat ion of functional
hypoxia response elements in the promoter region of the DEC1 and
DEC2 genes. J Biol Chem. 277:47014–47021. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gorski JP and Price JL: Bone muscle
crosstalk targets muscle regeneration pathway regulated by core
circadian transcriptional repressors DEC1 and DEC2. Bonekey Rep.
5:8502016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato F, Bhawal UK, Yoshimura T and
Muragaki Y: DEC1 and DEC2 crosstalk between circadian rhythm and
tumor progression. J Cancer. 7:153–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sato F, Kawamura H, Wu Y, Sato H, Jin D,
Bhawal UK, Kawamoto T, Fujimoto K, Noshiro M, Seino H, et al: The
basic helix-loop-helix transcription factor DEC2 inhibits
TGF-β-induced tumor progression in human pancreatic cancer BxPC-3
cells. Int J Mol Med. 30:495–501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li P, Jia YF, Ma XL, Zheng Y, Kong Y,
Zhang Y, Zong S, Chen ZT and Wang YS: DEC2 suppresses tumor
proliferation and metastasis by regulating ERK/NF-kappaB pathway in
gastric cancer. Am J Cancer Res. 6:1741–1757. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu T, He N, Yang Y, Yin C, Sang N and Yang
Q: DEC2 expression is positively correlated with HIF-1 activation
and the invasiveness of human osteosarcomas. J Exp Clin Cancer Res.
34:222015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Q, Wu Y, Yoshizawa T, Yan X, Morohashi
S, Seino H, Kato Y and Kijima H: Basic helix-loop-helix
transcription factor DEC2 functions as an anti-apoptotic factor
during paclitaxel-induced apoptosis in human prostate cancer cells.
Int J Mol Med. 38:1727–1733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin L Gosparowicz MK and Wittekind C:
TNM classification of malignant tumours. 7th edition. (New York,
Wiley). 2009.
|
|
12
|
Feng C, Sun Y, Ding G, Wu Z, Jiang H, Wang
L, Ding Q and Wen H: PI3Kβ inhibitor TGX221 selectively inhibits
renal cell carcinoma cells with both VHL and SETD2 mutations and
links multiple pathways. Sci Rep. 5:94652015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jones J, Otu H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Barrett T, Troup DB, Wilhite SE, Ledoux P,
Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M,
Marshall KA, et al: NCBI GEO: Archive for high-throughput
functional genomic data. Nucleic Acids Res. 37:D885–D890. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomczak K, Czerwinska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol. 19:A68–A77. 2015.
|
|
20
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hay N: The Akt-mTOR tango and its
relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ozes ON, Akca H, Mayo LD, Gustin JA,
Maehama T, Dixon JE and Donner DB: A phosphatidylinositol
3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor
necrosis factor inhibition of insulin signaling through insulin
receptor substrate-1. Proc Natl Acad Sci USA. 98:4640–4645. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shaw RJ, Bardeesy N, Manning BD, Lopez L,
Kosmatka M, DePinho RA and Cantley LC: The LKB1 tumor suppressor
negatively regulates mTOR signaling. Cancer Cell. 1:91–99. 2004.
View Article : Google Scholar
|
|
27
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Y, Jones CR, Fujiki N, Xu Y, Guo B,
Holder JL Jr, Rossner MJ, Nishino S and Fu YH: The transcriptional
repressor DEC2 regulates sleep length in mammals. Science.
325:866–870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gery S and Koeffler HP: Circadian rhythms
and cancer. Cell Cycle. 9:1097–1103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Innominato PF, Palesh O, Dhabhar FS, Levi
F and Spiegel D: Regulation of circadian rhythms and
hypothalamic-pituitary-adrenal axis: An overlooked interaction in
cancer. Lancet Oncol. 11:816–817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Olkkonen J, Kouri VP, Hynninen J,
Konttinen YT and Mandelin J: Differentially expressed in
chondrocytes 2 (DEC2) increases the expression of IL-1β and is
abundantly present in synovial membrane in rheumatoid arthritis.
PLoS One. 10:e01452792015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakamura H, Tanimoto K, Hiyama K, Yunokawa
M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E and
Nishiyama M: Human mismatch repair gene, MLH1, is
transcriptionally repressed by the hypoxia-inducible transcription
factors. DEC1 and DEC2. Oncogene. 27:4200–4209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Montagner M, Enzo E, Forcato M, Zanconato
F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et
al: SHARP1 suppresses breast cancer metastasis by promoting
degradation of hypoxia-inducible factors. Nature. 487:380–384.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bigot P, Colli LM, Machiela MJ, Jessop L,
Myers TA, Carrouget J, Wagner S, Roberson D, Eymerit C, Henrion D,
et al: Functional characterization of the 12p12.1 renal
cancer-susceptibility locus implicates BHLHE41. Nat Commun.
7:120982016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huerta-Sanchez E, Degiorgio M, Pagani L,
Tarekegn A, Ekong R, Antao T, Cardona A, Montgomery HE, Cavalleri
GL, Robbins PA, et al: Genetic signatures reveal high-altitude
adaptation in a set of ethiopian populations. Mol Biol Evol.
30:1877–1888. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gossage L and Eisen T: Alterations in VHL
as potential biomarkers in renal-cell carcinoma. Nat Rev Clin
Oncol. 7:277–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vanharanta S, Shu W, Brenet F, Hakimi AA,
Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM and Massagué J:
Epigenetic expansion of VHL-HIF signal output drives multiorgan
metastasis in renal cancer. Nat Med. 19:50–56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schubeler D: Function and information
content of DNA methylation. Nature. 517:321–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Malumbres M, Perez de Castro I, Santos J,
Fernandez Piqueras J and Pellicer A: Hypermethylation of the cell
cycle inhibitor p15INK4b 3′-untranslated region interferes with its
transcriptional regulation in primary lymphomas. Oncogene.
18:385–396. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Smith JF, Mahmood S, Song F, Morrow A,
Smiraglia D, Zhang X, Rajput A, Higgins MJ, Krumm A, Petrelli NJ,
et al: Identification of DNA methylation in 3′ genomic regions that
are associated with upregulation of gene expression in colorectal
cancer. Epigenetics. 2:161–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
